Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 2/20 | 1.00 |
| ▸ | JAK2 | O60674 | 9/20 | 0.55 |
| ▸ | JAK3 | P52333 | 9/20 | 0.55 |
| ▸ | LCK | P06239 | 5/20 | 0.55 |
| ▸ | CDK9 | P50750 | 2/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.55 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | PAK4 | O96013 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | FYN | P06241 | 1/20 | 0.55 |
| ▸ | CSF1R | P07333 | 1/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.55 |
| ▸ | IGF1R | P08069 | 1/20 | 0.55 |
| ▸ | MET | P08581 | 1/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13666776 | 1.00 | AURKA (1.00) | AURKAAURKBJAK2JAK3LCK | |
| SCHEMBL13313163 | 1.00 | AURKA (1.00) | AURKAAURKBJAK2JAK3LCK | |
| SCHEMBL3137876 | 0.91 | AURKA (0.83) | AURKAAURKBJAK2JAK3LCK | |
| SCHEMBL5590529 | 0.91 | AURKA (0.83) | AURKAAURKBJAK2JAK3LCK | |
| SCHEMBL3145171 | 0.91 | AURKA (0.83) | AURKAAURKBJAK2JAK3LCK | |
| SCHEMBL6527997 | 0.89 | AURKA (0.80) | AURKAAURKBJAK2JAK3LCK | |
| SCHEMBL13666779 | 0.89 | AURKA (0.80) | AURKAAURKBJAK2JAK3LCK | |
| SCHEMBL6525795 | 0.89 | AURKA (0.80) | AURKAAURKBJAK2JAK3LCK | |
| SCHEMBL3143501 | 0.89 | AURKA (0.80) | AURKAAURKBJAK2JAK3LCK | |
| SCHEMBL3144850 | 0.89 | AURKA (0.80) | AURKAAURKBJAK2JAK3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1511742-B1 | KINASE INHIBITORS | CYTOPIA RES PTY LTD (AU) | 2010-02-03 | — | — | EP | claimed |
| US-7259179-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2007-08-21 | — | — | US | claimed |
| US-20070161635-A1 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2007-07-12 | — | — | US | claimed |
| EP-1511742-A1 | KINASE INHIBITORS | Cytopia PTY Ltd (AU) | 2005-03-09 | — | — | EP | claimed |
| US-20050004140-A1 | Kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2005-01-06 | — | — | US | claimed |
| WO-2003099811-A1 | KINASE INHIBITORS | CYTOPIA PTY LTD (AU) | 2003-12-04 | — | — | WO | claimed |
| EP-1511742-B1 | KINASE INHIBITORS | CYTOPIA RES PTY LTD (AU) | 2010-02-03 | — | — | EP | disclosed |
| US-7598272-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2009-10-06 | — | — | US | disclosed |
| US-7511047-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2009-03-31 | — | — | US | disclosed |
| US-7259179-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2007-08-21 | — | — | US | disclosed |
| US-20070161635-A1 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2007-07-12 | — | — | US | disclosed |
| US-20060270687-A1 | Kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2006-11-30 | — | — | US | disclosed |
| US-20060241112-A1 | Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2006-10-26 | — | — | US | disclosed |
| EP-1511742-A1 | KINASE INHIBITORS | Cytopia PTY Ltd (AU) | 2005-03-09 | — | — | EP | disclosed |
| US-20050004140-A1 | Kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2005-01-06 | — | — | US | disclosed |
| WO-2003099811-A1 | KINASE INHIBITORS | CYTOPIA PTY LTD (AU) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270687-A1 | Kinase inhibitors | MAP3K20, MAP3K1, MAP3K19 | AURKA 327/4885AURKB 349/4885JAK2 272/4885 |
| US-20060241112-A1 | Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states | MAP4K2, MAP4K5, MAP4K4 | AURKA 440/4885AURKB 448/4885JAK2 616/4885 |
| US-20050004140-A1 | Kinase inhibitors | MAP3K20, MAP3K1, MAP3K19 | AURKA 327/4885AURKB 349/4885JAK2 272/4885 |
| US-20070161635-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K10 | AURKA 358/4885AURKB 352/4885JAK2 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.